Fast Five Quiz: Chronic Obstructive Pulmonary Disease Maintenance Therapy

Zab Mosenifar, MD


July 22, 2022

GOLD guidelines recommend triple therapy with ICS/LABA/LAMA for patients who have dyspnea or exercise tolerance despite dual therapy with LABA/LAMA. A 2018 meta-analysis by Cazzola and colleagues had shown that the ICS/LABA/LAMA combination was superior for reducing the risk for COPD exacerbation and improving forced expiratory volume compared with LABA/LAMA combination therapy.

A fixed-dose ICS/LABA/LAMA combination inhaler is available, per López-Campos and colleagues. Triple therapy can also be administered by using the three drugs separately in three inhalation devices or combining ICS/LABA with a LAMA or LABA/LAMA with ICS in two inhalation devices.

According to Ferguson and colleagues, a subanalysis of the ETHOS trial demonstrated the benefits of a triple fixed-dose ICS/LABA/LAMA combination extended to patients with moderate as well as severe COPD.

Learn more about triple therapy for the maintenance of COPD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.